AKTing on XPO1 inhibition in AML

被引：0
|
作者：
Goellner, Stefanie [1 ]
Mueller-Tidow, Carsten [1 ,2 ,3 ,4 ]
机构：
[1] Univ Hosp Heidelberg, Dept Med Hematol Oncol & Rheumatol 5, Heidelberg, Germany
[2] European Mol Biol Lab, Mol Med Partnership Unit, Heidelberg, Germany
[3] Heidelberg Univ, Heidelberg, Germany
[4] Natl Ctr Tumor Dis, Heidelberg, Germany
来源：
NATURE CANCER | 2022年 / 3卷 / 07期
关键词：
NUCLEAR EXPORT; C/EBP-BETA; EXPRESSION; CRM1;
D O I：
10.1038/s43018-022-00395-w
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Inhibition of XPO1-mediated nuclear export by selinexor represents a promising therapeutic strategy in acute myeloid leukemia. Because XPO1 is not specific for tumor-suppressive proteins, selinexor may also activate pro-oncogenic processes. A study now shows that inhibition of selinexor-induced, purinergic receptor-mediated AKT activation potentiates its anti-leukemic activity.
引用
收藏
页码：787 / 789
页数：3
相关论文
共 50 条
  • [31] Targeting metabolic vulnerabilities of endocrine resistant breast cancers using XPO1 and NAMPT inhibition.
    Zuo, Qianying
    Mogol, Ayca
    Imir, Ozan
    Landesman, Yosef
    Erdogan, Zeynep Madak
    CANCER RESEARCH, 2021, 81 (13)
  • [32] XPO1 inhibitor, KPT-8602, is well tolerated and highly active against AML blasts and LICs.
    Etchin, Julia
    Berezovskaya, Alla
    Conway, Amy S.
    Galinsky, Ilene A.
    Stone, Richard M.
    Baloglu, Erkan
    Senapedis, William
    Landesman, Yosef
    Kauffman, Michael
    Shacham, Sharon
    Wang, Jean C. Y.
    Look, A. Thomas
    CLINICAL CANCER RESEARCH, 2017, 23 (24) : 60 - 60
  • [33] Deconstructing protein and gene expression pathways to define the anticancer effects of XPO1 inhibition in ovarian cancer
    Evans, Brad R.
    Silvers, Thomas R.
    Chen, Ying A.
    Garcia, Jason
    Camacho, Catalina
    Sharp, Andrew J.
    Garag, Paras
    Koduru, Srinivas V.
    Billaud, Jean-Noel
    Halpert, Richard L.
    Dottino, Peter R.
    Landesman, Yosef
    Shacham, Sharon
    Martignetti, John A.
    CANCER RESEARCH, 2015, 75
  • [34] Inhibition of XPO1 impairs cholangiocarcinoma cell proliferation by triggering p53 intranuclear accumulation
    Zhao, Cheng
    Ma, Ben
    Yang, Zi-yi
    Li, Ou
    Liu, Shi-lei
    Pan, Li-jia
    Gong, Wei
    Dong, Ping
    Shu, Yi-jun
    CANCER MEDICINE, 2023, 12 (05): : 5751 - 5763
  • [35] XPO1 Inhibition Disrupts Ribosomal Subunits Assembly and Induces Multiple Myeloma (MM) Cell Death
    Tagoug, Ines
    Neri, Paola
    Slaby, Jiri
    Babich, Jacquelyn
    Simms, Justin
    Gratton, Kathy
    Ren, Li
    Bahlis, Nizar J.
    BLOOD, 2013, 122 (21)
  • [36] Inhibition of exportin 1 (XPO1) by selinexor (KPT-330) synergistically suppresses growth of neuroblastoma in combination with doxorubicin or bromodomain inhibition
    Ranieri, Pietro J.
    Trillo, Rebecca
    Landesman, Yosef
    Senapedis, William
    McCauley, Dilara
    Shacham, Sharon
    Kauffman, Michael
    Maris, John M.
    Attiyeh, Edward F.
    CANCER RESEARCH, 2015, 75
  • [37] XPO1 Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells
    Taylor-Kashton, Cheryl
    Lichtensztejn, Daniel
    Baloglu, Erkan
    Senapedis, William
    Shacham, Sharon
    Kauffman, Michael G.
    Kotb, Rami
    Mai, Sabine
    JOURNAL OF CELLULAR PHYSIOLOGY, 2016, 231 (12) : 2711 - 2719
  • [38] Discovery, Validation and Mechanistic Study of XPO1 Inhibition in the Treatment of Triple-Negative Breast Cancer
    Paulson, Amy L.
    Gruener, Robert F.
    Lee, Adam M.
    Huang, R. Stephanie
    CANCERS, 2024, 16 (23)
  • [39] Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer
    Chen, Ying
    Camacho, Sandra Catalina
    Silvers, Thomas R.
    Razak, Albiruni R. A.
    Gabrail, Nashat Y.
    Gerecitano, John F.
    Kalir, Eva
    Pereira, Elena
    Evans, Brad R.
    Ramus, Susan J.
    Huang, Fei
    Priedigkeit, Nolan
    Rodriguez, Estefania
    Donovan, Michael
    Khan, Faisal
    Kalir, Tamara
    Sebra, Robert
    Uzilov, Andrew
    Chen, Rong
    Sinha, Rileen
    Halpert, Richard
    Billaud, Jean-Noel
    Shacham, Sharon
    McCauley, Dilara
    Landesman, Yosef
    Rashal, Tami
    Kauffman, Michael
    Mirza, Mansoor R.
    Mau-Sorensen, Morten
    Dottino, Peter
    Martignetti, John A.
    CLINICAL CANCER RESEARCH, 2017, 23 (06) : 1552 - 1563
  • [40] PRECLINICAL AND CLINICAL EFFICACY OF KPT-330-MEDIATED XPO1 INHIBITION IN PH plus LEUKEMIAS
    Walkers, C.
    Oaks, J.
    Santhanam, R.
    Neviani, P.
    Harb, J.
    Ferenchak, G.
    Ellis, J.
    Landesman, Y.
    Reid, A.
    Milojkovic, D.
    Goldman, J.
    Apperley, J.
    Garzon, R.
    Marcucci, G.
    Gabrail, N.
    Smith, C.
    Shacham, S.
    Kauffman, M.
    Perrotti, D.
    HAEMATOLOGICA, 2013, 98 : 254 - 255
12345